Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 5/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920559 | 0.92 | HTR6 (0.37) | KRASBAZ2BHTR6NAMPTPTGDR2 | |
| SCHEMBL14729250 | 0.92 | KRAS (0.37) | KRASBAZ2BHTR6MAPK8NAMPT | |
| SCHEMBL6921931 | 0.91 | KRAS (0.35) | KRASHTR6NAMPTPTGDR2KDM4C | |
| SCHEMBL6922089 | 0.89 | KRAS (0.35) | KRASHTR6MAPK8NAMPTPTGDR2 | |
| SCHEMBL15087551 | 0.87 | BAZ2B (0.35) | KRASBAZ2BHTR6MAPK8NAMPT | |
| SCHEMBL14729252 | 0.86 | BAZ2B (0.39) | BAZ2BHTR6MAPK8CNR2 | |
| SCHEMBL15087611 | 0.85 | BAZ2B (0.35) | KRASBAZ2BHTR6MAPK8CNR2 | |
| SCHEMBL13834549 | 0.84 | HTR6 (0.39) | KRASBAZ2BHTR6PTGDR2KDM4C | |
| SCHEMBL15087555 | 0.82 | HTR6 (0.36) | HTR6 | |
| SCHEMBL14729251 | 0.82 | FNTA (0.38) | BAZ2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006234-B2 | Bridged heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8815843-B2 | Compounds and methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815843-B2 | Compounds and methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190359-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | KRAS 1316/4885BAZ2B 1270/4885HTR6 22/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | KRAS 3056/4885BAZ2B 669/4885HTR6 88/4885 |
| US-20130172366-A1 | BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRH4, HNMT, HTR2C | KRAS 1316/4885BAZ2B 1270/4885HTR6 22/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | KRAS 4179/4885BAZ2B 576/4885HTR6 47/4885 |
| US-20140088086-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | KRAS 4179/4885BAZ2B 576/4885HTR6 47/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | KRAS 3036/4885BAZ2B 664/4885HTR6 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.